

78877/780,3 U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office SEARCH REQUEST FORM

Requestor's Name: DONNA WORTMAN Serial Number: 09/909062
 Date: 10/28/02 Phone: 308-1032 Art Unit: 1648

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Please search the attached compound which is disclosed as a hepatitis C NS3 protease inhibitor.

Start Donna

Mary Jane Ruhl
Tech. Info. Specialist, STIC
TC-1600
CM-1, Room 6A-06
Phone: 605-1155

STAFF USE ONLY

Date completed: 10/29/02
 Searcher: Ruhl
 Terminal time: _____
 Elapsed time: _____
 CPU time: _____
 Total time: _____
 Number of Searches: _____
 Number of Databases: _____

Search Site

____ STIC
 ____ CM-1
 ____ Pre-S

Type of Search

____ N.A. Sequence
 ____ A.A. Sequence
 ____ Structure
 ____ Bibliographic

Vendors

____ IG
 ____ STN
 ____ Dialog
 ____ APS
 ____ Geninfo
 ____ SDC
 ____ DARC/Questel
 ____ Other

BEST AVAILABLE COPY

=> d his

(FILE 'HOME' ENTERED AT 15:17:36 ON 29 OCT 2002)

FILE 'REGISTRY' ENTERED AT 15:17:47 ON 29 OCT 2002


L1 1 S 149885-80-3/RN
L2 STR
L3 14 S L2
L4 229 S L2 FULL
L5 9 S L4 AND O>10
L6 3 S L5 AND NR=2
L7 1 S 393520-91-7

- This complt., retrieved in L6, matches the search request

FILE 'HCAPLUS' ENTERED AT 15:51:41 ON 29 OCT 2002

L8 1 S L7 *1 cit in CA Plus - attached*

=> d que stat 16
L2 STR



*This is the str. fragment I
used to search*

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

L4 229 SEA FILE=REGISTRY SSS FUL L2 *229 hits for fragment*
L5 9 SEA FILE=REGISTRY ABB=ON L4 AND O>10 *9 hits for Oxygen >10*
L6 3 SEA FILE=REGISTRY ABB=ON L5 AND NR=2 *3 " " rings limited to 2*

=> d ibib abs hitstr 1

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:90074 HCAPLUS

DOCUMENT NUMBER: 136:151440

TITLE: Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Liu, Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto, Patrick A.; Njoroge, F. George; Ganguly, Ashit K.; Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita

PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.

SOURCE: PCT Int. Appl., 197 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008256	A2	20020131	WO 2001-US22826	20010719
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2000-220109P P 20000721

OTHER SOURCE(S): MARPAT 136:151440

GI



AB Novel peptides I [Z = O, NH or substituted imino; X = (un)substituted alkylsulfonyl, heterocyclysulfonyl, heterocyclylalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, arylcarbonyl, heteroarylcabonyl, alkoxy carbonyl, heterocyclloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkyaminocarbonyl, heterocyclylaminocarbonyl, arylaminocarbonyl, or heteroarylamino carbonyl; X1 = H, alkyl, arylmethyl; P1a, P1b, P2-P6 = H, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; P1a and P1b may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring contg. 0-6 oxygen, nitrogen, sulfur, or phosphorus atoms; P1' = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] having HCV protease inhibitory activity are disclosed. Thus, peptide II was prepd. via peptide coupling in soln. and showed $K_i = 1-100$ nM for inhibition of HCV protease.

IT **393520-91-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393520-91-7 HCAPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

